Veralox Therapeutics is a clinical stage biotechnology company based in Frederick, MD, dedicated to developing innovative drug products targeting the 12-Lipoxygenase pathway. Their therapies aim to address life-threatening immuno-inflammatory diseases such as Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D) by inhibiting the production of proinflammatory metabolites through the 12-LOX enzyme.
With a focus on developing disease-modifying therapies, Veralox Therapeutics is committed to shutting down the production of harmful metabolites and promoting proper cellular function. Their clinical program in HIT and preclinical program in T1D, along with ongoing discovery research, demonstrate their dedication to expanding the use of their 12-LOX inhibitors to combat a wide range of diseases.
Generated from the website